登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C24H26BrN3O3
化学文摘社编号:
分子量:
484.39
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
尼麦角林, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C24H26BrN3O3/c1-27-13-17-8-21-24(30-3,19-5-4-6-20(27)22(17)19)9-15(12-28(21)2)14-31-23(29)16-7-18(25)11-26-10-16/h4-7,10-11,13,15,21H,8-9,12,14H2,1-3H3/t15-,21-,24+/m1/s1
SMILES string
[H][C@@]12Cc3cn(C)c4cccc(c34)[C@]1(C[C@@H](COC(=O)c5cncc(Br)c5)CN2C)OC
InChI key
YSEXMKHXIOCEJA-FVFQAYNVSA-N
grade
pharmaceutical primary standard
API family
nicergoline
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
Application
Nicergoline EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Warning
hcodes
pcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
A Moretti et al.
Arzneimittel-Forschung, 29(8a), 1223-1227 (1979-01-01)
10-Methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) shows a strong alpha-blocking activity both in vitro and in vivo. Various studies (dog, cat, rabbit, rat, mouse, guinea-pig) show that nicergoline affects only slightly blood pressure and heart rate and increases the blood flow in
[Therapeutic potential and possibilities of using of sermion (nicergoline) in neurological practice].
I V Damulin
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 110(12), 119-122 (2010-01-01)
Bengt Winblad et al.
Clinical drug investigation, 28(9), 533-552 (2008-08-01)
The ergot alkaloid derivative nicergoline became clinically available about 35 years ago in the 1970s. Nicergoline has a broad spectrum of action: (i) as an alpha(1)-adrenoceptor antagonist, it induces vasodilation and increases arterial blood flow; (ii) it enhances cholinergic and
Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art.
R G Fariello
Functional neurology, 12(3-4), 221-225 (1997-05-01)
M Fioravanti et al.
The Cochrane database of systematic reviews, (4)(4), CD003159-CD003159 (2001-11-01)
Nicergoline is an ergot derivative currently in use in over fifty countries for more than three decades, for the treatment of cognitive, affective, and behavioral disorders of older people. It was initially considered as a vasoactive drug and mainly prescribed
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持